Changeflow GovPing Healthcare & Life Sciences CDER Request for Information Docket FDA-2026-E-...
Routine Consultation Added Consultation

CDER Request for Information Docket FDA-2026-E-4491

Favicon for www.regulations.gov Regs.gov: Food and Drug Administration
Published
Detected
Email

Summary

The FDA Center for Drug Evaluation and Research (CDER) issued a Request for Information under Docket FDA-2026-E-4491, soliciting public comments on matters within CDER's regulatory purview. The document was posted on regulations.gov with an attached PDF containing the full RFI text. No other documents were available for viewing or download at time of access.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

Every FDA document on regulations.gov, the federal rulemaking portal. This is where the agency posts variances, advisory committee meeting notices, draft guidance for comment, citizen petition responses, and procedural rules that do not get a separate Federal Register slot. Around 240 a month. FDA's heavy regulations.gov use means tracking only the Federal Register misses a meaningful chunk of what the agency does day-to-day. Watch this if you manufacture devices, submit IND or NDA applications, run a lab, or advise sponsors on FDA process. GovPing publishes each posting with the docket, document type, division (CDER, CDRH, CFSAN), and comment window where one applies.

What changed

CDER has initiated a Request for Information process for Docket FDA-2026-E-4491. The source materials indicate only that CDER authored the RFI and posted it to regulations.gov; the specific subject matter of the inquiry is not visible in the available source content. Interested parties should monitor regulations.gov for the full RFI document and any associated Federal Register notice providing context on the specific regulatory topic under consideration.

Affected parties—including pharmaceutical manufacturers, drug manufacturers, and clinical investigators—should review the complete RFI once published to determine whether their operations or products fall within the scope of CDER's inquiry and assess whether submission of comments is warranted.

Archived snapshot

Apr 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

There are no documents available to view or download

Attachments 1

Request for Information

More Information
- Author(s) CDER
Download

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Published
January 1st, 2026
Instrument
Consultation
Branch
Executive
Legal weight
Non-binding
Stage
Consultation
Change scope
Minor
Docket
FDA-2026-E-4491

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Regulatory consultation Public comment solicitation
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Healthcare Public Health

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!